On the 1st, SK Bioscience announced that it has submitted an application for a Conditional Marketing Authorization (CMA) of its COVID-19 vaccine, ‘SKYCovion,' to the European Medicines Agency (EMA),

SKYCovion is a COVID-19 vaccine that induces neutralizing antibody responses by administering an antibody protein made with SK Bioscience’s recombinant protein vaccine technology. SKYCovion was developed with SK Bioscience’s recombinant protein vaccine technology and the ‘self-assembly nanoparticle’ design technology of the Institute for Protein Design (IPD) at the University of Washington School of Medicine.

From the initial stages of development, SKYCovion has been supported by fundi